4503N Stock Chart & Stats
$253.57
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$204.11 - $281.91
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$418.95B
Enterprise Value$4.92M
Total Cash (Recent Filing)$281.61B
Total Debt (Recent Filing)$565.95B
Price to Earnings (P/E)13.3
Beta-0.06
Next Earnings
Aug 05, 2026EPS Estimate
5.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)162.77
Shares Outstanding1,809,663,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.46
Price to Sales (P/S)2.11
P/FCF Ratio8.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$255.98Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
4503N FAQ
What was Astellas Pharma’s price range in the past 12 months?
Astellas Pharma lowest stock price was $204.11 and its highest was $281.91 in the past 12 months.
What is Astellas Pharma’s market cap?
Astellas Pharma’s market cap is $418.95B.
When is Astellas Pharma’s upcoming earnings report date?
Astellas Pharma’s upcoming earnings report date is Aug 05, 2026 which is in 11 days.
How were Astellas Pharma’s earnings last quarter?
Astellas Pharma released its earnings results on Apr 27, 2026. The company reported $2.598 earnings per share for the quarter, missing the consensus estimate of $3.27 by -$0.672.
Is Astellas Pharma overvalued?
According to Wall Street analysts Astellas Pharma’s price is currently Undervalued.
Does Astellas Pharma pay dividends?
Astellas Pharma does not currently pay dividends.
What is Astellas Pharma’s EPS estimate?
Astellas Pharma’s EPS estimate is 5.51.
How many shares outstanding does Astellas Pharma have?
Astellas Pharma has 1,809,663,100 shares outstanding.
What happened to Astellas Pharma’s price movement after its last earnings report?
Astellas Pharma reported an EPS of $2.598 in its last earnings report, missing expectations of $3.27. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Astellas Pharma?
Currently, no hedge funds are holding shares in MX:4503N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astellas Pharma
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.
4503N Stock 12 Month Forecast
Average Price Target
$255.98